Key Highlights:
- Award-Winning Innovation: AccurECG™ wins “Best New Technology Solution for ECG” at the 9th MedTech Breakthrough Awards.
- AI-Powered Diagnostic Leap: Platform offers near real-time, beat-by-beat ECG analysis across multiple arrhythmias, supporting early detection.
- FDA Breakthrough Designations: Two novel AI-based diagnostic tools—AK-AVS™ and AK+ Guard™—strengthen AccurKardia’s cardiac care pipeline.
A Landmark Recognition for a Game-Changing ECG Technology
AccurKardia’s AccurECG™ has been named the “Best New Technology Solution for ECG” by the 2025 MedTech Breakthrough Awards, a prestigious global program that celebrates excellence in digital health innovation. This recognition cements AccurKardia’s leadership in transforming traditional ECG diagnostics with AI-driven precision, accessibility, and scale.
Real-Time, Vendor-Neutral ECG Analysis Platform
AccurECG™ delivers automated, near real-time beat-by-beat ECG analysis across various arrhythmias, including atrial fibrillation and flutter. Device-agnostic and API-integrated, it seamlessly fits into clinical workflows—reducing turnaround time and enhancing arrhythmia detection. This flexible software-as-a-medical-device (SaMD) redefines how cardiac events are monitored and diagnosed.
FDA Breakthrough Designations Expand the Diagnostic Horizon
AccurKardia is extending the clinical utility of ECGs with two investigational AI-powered tools:
- AK-AVS™: Screens for moderate to severe Aortic Valve Stenosis, a condition with high mortality if left undetected.
- AK+ Guard™: Detects hyperkalemia via Lead I ECG, enabling early intervention for potentially fatal electrolyte imbalances.
Both tools received FDA Breakthrough Device Designation and are in development for broader clinical applications.
Vision to Turn ECGs Into Predictive Biomarkers
AccurKardia’s CEO Juan C. Jimenez emphasized the company’s mission to elevate ECGs as predictive biomarkers across cardiac and systemic diseases. “We are committed to expanding access to high-precision cardiac diagnostics and pushing ECG analytics into the next frontier of preventive medicine,” he stated.
With its innovations, regulatory milestones, and industry recognition, AccurKardia is poised to become a pivotal player in reshaping digital cardiology.
About AccurKardia
AccurKardia is a pioneering ECG-led diagnostics company developing AI-driven tools for early cardiac event detection. Its flagship platform, AccurECG™, is FDA-cleared and integrates into diverse care environments. The company’s investigational technologies—AK+ Guard™ and AK-AVS™—target serious conditions like hyperkalemia and aortic valve stenosis. Visit www.accurkardia.com to learn more.
About MedTech Breakthrough
The MedTech Breakthrough Awards honor top digital health and medical technology innovators across more than 18 countries. The program spans categories such as telehealth, diagnostics, and connected care. Learn more at MedTechBreakthrough.com.
By